Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)PRNewsWire • 10/14/21
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021PRNewsWire • 10/06/21
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMSPRNewsWire • 10/01/21
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate UpdatePRNewsWire • 08/05/21
BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in IsraelPRNewsWire • 07/27/21
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate UpdatePRNewsWire • 07/26/21
Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major MarketsPRNewsWire • 06/15/21
Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMSSeeking Alpha • 05/30/21
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL MeetingPRNewsWire • 05/25/21
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/26/21
BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate UpdatePRNewsWire • 04/26/21
BrainStorm to Announce First Quarter Financial Results and Provide a Corporate UpdatePRNewsWire • 04/19/21
BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MSPRNewsWire • 03/24/21
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) InvestigationBusiness Wire • 02/26/21
FDA Concludes BrainStorm's ALS Cell Therapy Lacks Substantial Data For Submission; Shares DropBenzinga • 02/22/21
BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development ProgramPRNewsWire • 02/22/21
Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/04/21
BrainStorm Announces Full Year 2020 Financial Results and Provides a Corporate UpdatePRNewsWire • 02/04/21
BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDSPRNewsWire • 01/20/21